2023
Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
Ragon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Al Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.Peer-Reviewed Original ResearchConceptsSecond hematological malignanciesSecond primary malignanciesProgression-free survivalMultiple myelomaOverall survivalMaintenance therapyDevelopment of SPMsRisk of SPMAutologous hematopoietic stem cell transplantationInferior progression-free survivalHematopoietic stem cell transplantationHigh-dose melphalanMelphalan conditioning regimenSubsequent maintenance therapyStem cell transplantationFrequent primary causeCIBMTR analysisLenalidomide maintenanceAuto-HSCTConditioning regimenMedian survivalPrimary malignancyAdult patientsCell transplantationClinical trialsFemale Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
Meacham L, George S, Veludhandi A, Pruett M, Haight A, Arnold S, Elchuri S, Stenger E, Krishnamurti L. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning? Transplantation And Cellular Therapy 2023, 29: 531.e1-531.e4. PMID: 37169288, DOI: 10.1016/j.jtct.2023.05.004.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationReduced-intensity conditioningPremature ovarian insufficiencySickle cell diseaseNormal AMH levelsMyeloablative conditioningAnti-Müllerian hormoneOvarian outcomeAMH levelsCell transplantationCell diseaseRIC HCTFollicle-stimulating hormone levelsPediatric oncology patientsRisk of infertilityMIU/mLStudy 2 patientsReproductive health outcomesMelphalan regimenConditioning regimenGonadal damageOvarian damageConditioning regimensOvarian reserveRIC regimens
2018
Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu X, Dimopoulos M, Sonneveld P, Ho P, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min C, Schecter J, Jansson R, Zhang L, Sun Y, Clemens P. Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Advances In Therapy 2018, 35: 1859-1872. PMID: 30374808, PMCID: PMC6223994, DOI: 10.1007/s12325-018-0815-9.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDose-Response Relationship, DrugFemaleFinlandHumansLenalidomideMaleMelphalanMiddle AgedMultiple MyelomaNeutropeniaProgression-Free SurvivalThalidomideTreatment OutcomeConceptsProgression-free survivalDaratumumab exposureCombination therapyDosing scheduleMultiple myelomaAdverse eventsMonoclonal antibody targeting CD38Standard-of-care regimensDose of daratumumabNo dose adjustmentCombination therapy regimensPopulation pharmacokinetic analysisExposure-safety relationshipMaximal clinical benefitDisease-related covariatesEfficacy/safety outcomesIntravenous daratumumabResultsPharmacokinetic profilesExposure-response analysesDose adjustmentTherapy regimensClinical benefitDaratumumabExposure-efficacyPivotal studies
2017
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation
Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood 2017, 130: 1383-1386. PMID: 28698204, DOI: 10.1182/blood-2017-06-788729.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light ChainsImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedMolecular Targeted TherapyParaproteinsRecurrenceRetrospective StudiesSalvage TherapyLong‐term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era
Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long‐term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatric Blood & Cancer 2017, 64 PMID: 28646513, DOI: 10.1002/pbc.26696.Peer-Reviewed Original ResearchConceptsGroup D eyesGroup D retinoblastoma eyesD eyesSystemic chemoreductionIntravitreal melphalanSalvage rateRetinoblastoma eyesIntravitreal melphalan injectionRetrospective chart reviewOverall salvage ratePrimary outcome measurementLong-term outcomesExternal beam radiationOcular salvageSalvage therapyVitreous seedsChart reviewGlobe salvageIntravitreal injectionKaplan-MeierTreatment modalitiesTumor recurrenceMelphalan injectionOutcome measurementsMelphalanNot All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma
Berry JL, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, Kim JW. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Ophthalmology 2017, 124: 1817-1825. PMID: 28655537, DOI: 10.1016/j.ophtha.2017.05.034.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChildChild, PreschoolCryotherapyEtoposideFemaleFollow-Up StudiesHumansInfantInfusions, IntravenousIntravitreal InjectionsLaser CoagulationMaleMelphalanNeoplasm SeedingRetinal NeoplasmsRetinoblastomaRetrospective StudiesSalvage TherapyVincristineVitreous BodyConceptsIntra-arterial chemotherapyIntravitreal melphalanIntravenous chemotherapyVitreous seedingSalvage rateRetrospective reviewIVM injectionsOverall globe salvage ratePrimary intra-arterial chemotherapyGlobe salvage rateNonrandomized retrospective reviewOutcome of retinoblastomaRecurrent vitreous seedingPrimary outcome measureActive retinoblastomaVitreous seedsGlobe salvageIntravitreal chemotherapySingle centerIntravitreal injectionMore injectionsGrade 3Outcome measuresSecondary measuresEffective treatmentMycobacterium genavense‐induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature
Coelho R, Hanna R, Flagg A, Stempak LM, Ondrejka S, Procop GW, Harrington S, Zembillas A, Kusick K, Gonzalez BE. Mycobacterium genavense‐induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature. Transplant Infectious Disease 2017, 19 PMID: 28039955, DOI: 10.1111/tid.12656.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAbdomenAdolescentAlemtuzumabAntibiotic ProphylaxisAntibiotics, AntitubercularAntibodies, Monoclonal, HumanizedBone Marrow TransplantationBronchoalveolar Lavage FluidCyclosporineDiabetes Mellitus, Type 1DiarrheaGenetic Diseases, X-LinkedGraft RejectionGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistiocytesHumansImmune System DiseasesImmunosuppressive AgentsLymph NodesMaleMelphalanMycobacterium Infections, NontuberculousMycophenolic AcidNontuberculous MycobacteriaPhotopheresisPolymerase Chain ReactionTransplantation ConditioningVidarabine
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairmentInfusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2015
Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart
Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology 2015, 33: 3689-3690. PMID: 26371139, DOI: 10.1200/jco.2015.63.2224.Peer-Reviewed Original Research
2012
The use of isolated limb infusion in limb threatening extremity sarcomas
Vohra N, Turaga K, Gonzalez R, Conley A, Reed D, Bui M, Cheong D, Letson D, Zager J. The use of isolated limb infusion in limb threatening extremity sarcomas. International Journal Of Hyperthermia 2012, 29: 1-7. PMID: 23205633, PMCID: PMC4509503, DOI: 10.3109/02656736.2012.740548.Peer-Reviewed Original ResearchConceptsIsolated limb infusionExtremity soft tissue sarcomaSoft tissue sarcomasStable diseaseComplete responsePartial responseTissue sarcomasDownstaged to resectable diseaseIn-field response rateLong-term follow-upResponse rateLimb preservationGrade III toxicityLimb salvageSingle-institution experienceIntra-operative parametersRegional disease controlOverall response rateSignificant treatment challengeShort-term resultsMedian followupResectable diseaseExtremity sarcomasFollow-upPatient characteristicsVerification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. Journal Of NeuroInterventional Surgery 2012, 5: e42. PMID: 23188789, DOI: 10.1136/neurintsurg-2012-010508.rep.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingCerebral AngiographyContrast MediaDrug Delivery SystemsFollow-Up StudiesGadoliniumHumansInfantInjections, Intra-ArterialIntraoperative PeriodMagnetic Resonance AngiographyMaleMelphalanRetinal ArteryRetinal DetachmentRetinal NeoplasmsRetinoblastomaTreatment OutcomeVisual AcuityVerification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. BMJ Case Reports 2012, 2012: bcr2012010508. PMID: 23162039, PMCID: PMC4545047, DOI: 10.1136/bcr-2012-010508.Peer-Reviewed Original Research
2011
Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms
Turaga K, Beasley G, Kane J, Delman K, Grobmyer S, Gonzalez R, Letson G, Cheong D, Tyler D, Zager J. Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. JAMA Surgery 2011, 146: 870-875. PMID: 21768436, PMCID: PMC4515974, DOI: 10.1001/archsurg.2011.139.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticAntineoplastic Agents, AlkylatingBiomarkers, TumorCarcinoma, Merkel CellCarcinoma, Squamous CellChemotherapy, Cancer, Regional PerfusionCreatine KinaseDactinomycinDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFollow-Up StudiesHumansLength of StayLimb SalvageMaleMelphalanMiddle AgedRetrospective StudiesSarcomaSkin NeoplasmsSoft Tissue NeoplasmsTreatment OutcomeYoung AdultConceptsSoft tissue malignant neoplasmIn-field response rateSerum creatinine phosphokinase levelsIsolated limb infusionCreatinine phosphokinase levelsSoft tissue sarcomasMalignant neoplasmsLimb preservationCell carcinomaResponse rateEfficacy of isolated limb infusionLocally advanced soft tissue sarcomasAdvanced soft tissue sarcomaShort-term response rateGrade IV toxicityResection of diseaseDurability of responseMedian follow-upMerkel cell carcinomaRegional disease controlMedian length of staySquamous cell carcinomaCutaneous malignant neoplasmsLimb preservation ratesSignificant treatment challenge
2006
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients. Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmbulatory CareAnti-Bacterial AgentsAntibiotic ProphylaxisAntineoplastic Agents, AlkylatingBacteremiaCeftriaxoneDose-Response Relationship, DrugFeverHospitalizationHumansIncidenceLength of StayMelphalanMiddle AgedMultiple MyelomaNeutropeniaRetrospective StudiesStaphylococcal InfectionsStem Cell TransplantationConceptsHigh-dose melphalanOnset of neutropeniaPrimary care providersOutpatient settingMean durationPeripheral blood progenitor cell infusionGeneral outpatient settingProgenitor cell infusionTreatment-related mortalityMultiple myeloma patientsUse of ceftriaxoneApparent beneficial effectTransplant episodesMost patientsCell infusionFebrile patientsMedian timeMyeloma patientsRandomized trialsDecreased riskOutpatient therapyAmbulatory therapyOutpatient treatmentNeutropeniaCare providers
2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansL-Lactate DehydrogenaseMaleMelphalanMiddle AgedPrognosisRecurrenceTransplantation, AutologousConceptsProgression-free survivalHigh-dose BEAM chemotherapyPeripheral blood progenitor cellsAutologous PBPC transplantationTime of transplantationPrimary refractoryHodgkin's diseaseHigh-dose BEAMBEAM chemotherapyPBPC transplantationOverall survivalAutologous peripheral blood progenitor cell transplantationAutologous peripheral blood progenitor cellsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationSatisfactory progression-free survivalSevere non-hematologic toxicityWorse progression-free survivalPoor progression-free survivalAutologous PBPC infusionNon-hematologic toxicitiesTransplant-related complicationsConsecutive adult patientsElevated lactate dehydrogenaseRelapse/progression
1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Costanza M, Weiss R, Henderson I, Norton L, Berry D, Cirrincione C, Winer E, Wood W, Frei III E, McIntyre O, Schilsky R. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. Journal Of Clinical Oncology 1999, 17: 1397-406. PMID: 10334524, DOI: 10.1200/jco.1999.17.5.1397.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdultAgedAminoglycosidesAnalysis of VarianceAnti-Bacterial AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinCyclophosphamideDoxorubicinFemaleFluorouracilFollow-Up StudiesHumansImidesIsoquinolinesMelphalanMiddle AgedNaphthalimidesNeoplasm StagingOrganophosphonatesProspective StudiesSurvival AnalysisTrimetrexateConceptsPhase II agentMetastatic breast cancer patientsStandard combination chemotherapyMetastatic breast cancerBreast cancer patientsSingle agentResponse rateCombination chemotherapyCancer patientsBreast cancerUntreated metastatic breast cancer patientsMeasurable metastatic breast cancerRandomized phase III trialPhase III trialsDuration of responseSingle-agent drugsTreatment of patientsCumulative response rateSuggestion of benefitLow response rateImmediate chemotherapyIII trialsMetastatic diseaseVisceral diseaseRandomized studyIntermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
COMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloidosisAntineoplastic Agents, AlkylatingDrug CombinationsFemaleGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukapheresisMaleMelphalanMiddle AgedSurvival AnalysisConceptsBlood stem cellsMobilization regimensG-CSFIntermediate dose (15-30 mg/m2, day 1) intravenous melphalanDose-intensive melphalanPhase 11 trialGrade 4 toxicityComplete haematological responseCells/AL amyloidosis patientsTerms of CD34Stem cellsActive regimenMobilization patientsDose melphalanOrgan involvementIntravenous melphalanCardiac amyloidD mortalityMonths 57AL amyloidosisAmyloidosis patientsHaematological responsePatientsDay 5Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits
1998
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisAntineoplastic Agents, AlkylatingCohort StudiesCombined Modality TherapyErythrocyte TransfusionFemaleHematopoietic Stem Cell TransplantationHumansKidneyLife TablesLiverMaleMelphalanMiddle AgedMyocardiumNervous SystemParaproteinsPlatelet TransfusionPrognosisRecurrenceSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTreatment OutcomeConceptsClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply